GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adynxx Inc (FRA:HL1C) » Definitions » Shiller PE Ratio

Adynxx (FRA:HL1C) Shiller PE Ratio : (As of Jun. 12, 2024)


View and export this data going back to 1998. Start your Free Trial

What is Adynxx Shiller PE Ratio?

Note: If the price history is too short, we do not calculate current Shiller PE for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Adynxx Shiller PE Ratio Historical Data

The historical data trend for Adynxx's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adynxx Shiller PE Ratio Chart

Adynxx Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Adynxx Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Adynxx's Shiller PE Ratio

For the Biotechnology subindustry, Adynxx's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adynxx's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adynxx's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Adynxx's Shiller PE Ratio falls into.



Adynxx Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Adynxx's E10 for the quarter that ended in Sep. 2019 is calculated as:

For example, Adynxx's adjusted earnings per share data for the three months ended in Sep. 2019 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2019 (Change)*Current CPI (Sep. 2019)
=0/108.3294*108.3294
=0.000

Current CPI (Sep. 2019) = 108.3294.

Adynxx Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
200912 -3.864 91.111 -4.594
201003 0.000 91.821 0.000
201006 0.000 91.962 0.000
201009 0.000 92.162 0.000
201012 -19.845 92.474 -23.248
201103 -18.716 94.283 -21.504
201106 0.000 95.235 0.000
201109 0.000 95.727 0.000
201112 -99.751 95.213 -113.492
201203 0.000 96.783 0.000
201206 -20.921 96.819 -23.408
201209 0.000 97.633 0.000
201212 -21.603 96.871 -24.158
201303 -20.844 98.209 -22.992
201306 -15.008 98.518 -16.503
201309 -13.913 98.790 -15.256
201312 -89.790 98.326 -98.925
201403 -31.667 99.695 -34.410
201406 -17.222 100.560 -18.553
201409 -15.365 100.428 -16.574
201412 -16.544 99.070 -18.090
201503 -26.611 99.621 -28.937
201506 -17.107 100.684 -18.406
201509 -13.900 100.392 -14.999
201512 -8.813 99.792 -9.567
201603 -15.086 100.470 -16.266
201606 9.612 101.688 10.240
201609 -16.305 101.861 -17.340
201612 -34.697 101.863 -36.900
201703 -12.735 102.862 -13.412
201706 -4.966 103.349 -5.205
201709 -2.819 104.136 -2.933
201712 -13.283 104.011 -13.834
201803 -5.791 105.290 -5.958
201806 -1.489 106.317 -1.517
201809 -0.771 106.507 -0.784
201812 -1.318 105.998 -1.347
201903 -0.903 107.251 -0.912
201906 0.000 108.070 0.000
201909 0.000 108.329 0.000

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Adynxx  (FRA:HL1C) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Adynxx Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Adynxx's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Adynxx (FRA:HL1C) Business Description

Traded in Other Exchanges
N/A
Address
100 Pine Street, Suite 500, San Francisco, CA, USA, 94111
Adynxx Inc is a United States-based clinical-stage biopharmaceutical company. It is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to the market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. Its pipeline includes brivoligide, a Phase 2 drug candidate intended to address postoperative pain, and AYX2, a pre-clinical candidate intended to treat chronic syndromes of pain, including both inflammatory and neuropathic pain.

Adynxx (FRA:HL1C) Headlines

No Headlines